Pfizer’s RSV vaccine shows strong response in immunocompromised adults
Pfizer’s (NYSE:PFE) respiratory syncytial virus (RSV) vaccine Abrysvo was well-tolerated and generated strong neutralizing ...
pharmaphorum6d
Pfizer seeks to overturn three RSV vaccine patents held by GSK
Already competing to bring the first vaccine against respiratory syncytial virus (RSV) to market, Pfizer and GSK are ... seeking to invalidate three GSK patients covering its RSVPreF3 shot ...
pharmaphorum6d
Pfizer bulks up in RSV with $525m takeover of ReViral
Pfizer is looking to follow its vaccine/oral antiviral combination that has proved so profitable in COVID-19 with a similar approach in respiratory syncytial virus (RSV). The drugmaker is in the ...
Hosted on MSN11mon
Pfizer reports top-line results from Phase III RSV vaccine trial
"Pfizer reports top-line results from Phase III RSV vaccine trial" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been ...
Barron's10mon
Pfizer to Ask FDA to Extend RSV Shot Approval to All Adults
Drug company Pfizer is seeking to expand the approval of its respiratory syncytial virus (RSV) vaccine to include adults over the age of 18.